Clinical Trials Or Observational Studies for Asthma? FDA Advisory Panels Can't Agree
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants to gather long-term safety data in long acting beta-2 adrenergic agonist asthma drugs.
You may also be interested in...
LABA Label Changes Could Reinvigorate Single-Ingredient Products
FDA's new labeling and use guidelines for long-acting beta agonists may present some sales challenges, but also may create a new market for older drugs
FDA Scales Back LABA Safety Relabeling To Address Physician Worries
FDA has modified the safety relabeling it is rolling out for long-acting beta agonists to reflect physician concerns that an abrupt discontinuation of the products could be harmful to patients
LABA Label Changes Could Reinvigorate Single-Ingredient Products
FDA's new labeling and use guidelines for long-acting beta agonists may present some sales challenges, but also may create a new market for older drugs